ReviewJournal of nephropathology2015
Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usage.
Review in Journal of nephropathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Alternate-Day Versus Consecutive-Day Anti-T Lymphocyte Globulin Induction in First Living-Donor Kidney Transplant Recipients at Low Immunological Risk: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Rabbit-Derived Antithymocyte Globulin-Associated Perioperative Anaphylaxis in Renal Transplantation: A Multidisciplinary Perspective on Pathophysiology, Clinical Presentation, and Management.Antibodies (Basel, Switzerland) · 2025Review
- Immunosuppressants/Immunomodulators and Malignancy.Journal of clinical medicine · 2025Review
- Evaluating ATG Induction Therapy Outcomes After Commercial Kidney Transplantation: Insights from a Tertiary Hospital Experience.Journal of clinical medicine · 2025Article
- Accurate Multiplex qPCR Detection of Epstein-Barr Virus/Cytomegalovirus/BK Virus in Kidney Transplant Patients: Pilot Study.International journal of molecular sciences · 2024Article
- Impact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistence.PLoS pathogens · 2024Article
- Impact of induction agents and maintenance immunosuppression on torque teno virus loads and year-one complications after kidney transplantation.Frontiers in immunology · 2024Article
- Viral load kinetics and the clinical consequences of cytomegalovirus in kidney transplantation.Frontiers in immunology · 2023Article
- Induction Therapy and Therapeutic Antibodies.Handbook of experimental pharmacology · 2022Article
- Sex-Associated Differences in Cytomegalovirus Prevention: Prophylactic Strategy is Potentially Associated With a Strong Kidney Function Impairment in Female Renal Transplant Patients.Frontiers in pharmacology · 2020Article
- Targeted preemptive therapy according to perceived risk of CMV infection after kidney transplantation.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesArticle
- Anti-Thymocyte Globulin Induced Acute Lung Injury in a Case of Renal Allograft Recipient.Indian journal of nephrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextPreventing acute rejection (AR) after kidney transplantation is of utmost importance because an AR can have a negative impact on long-term allograft survival. EVIDENCE ACQUISITION: Directory of Open Access Journals (DOAJ), Google Scholar, PubMed, EBSCO, and Web of Science have been searched.
resultsAt the moment this can be done by using rabbit anti-thymocyte globulins (rATGs) as an induction therapy. However, because rATGs are associated with some deleterious side-effects, such as the opportunistic infections cytomegalovirus (CMV) and de novo post-transplant cancer, it is very important they are used optimally, i.e., at minimal doses that avoid many side-effects but still retain optimal treatment efficacy. Recent data show that the risk of CMV infection can be minimized using tacrolimus plus everolimus, and not tacrolimus plus mycophenolic acid, as the maintenance immunosuppression. The use of rATG is particularly valuable in; (a) sensitized patients; (b) in recipients from an expanded-criteria donor, thus enabling the introduction of calcineurin inhibitors at reduced doses; and (c) for patients where steroid avoidance is contemplated. However, we also need to consider that rATG may increase the risk of de novo cancer, even though recent data indicate this is unlikely and that any risk can be reduced by using mammalian target of rapamycin (mTOR) inhibitors instead of mycophenolic acid combined with low-dose calcineurin inhibitors.
conclusionsEven though rATGs do not improve long-term kidney-allograft survival, they may help reduce calcineurin-inhibitor dosage during the early post-transplant period and minimize the risk of AR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.